Psyence Biomedical Ltd. Financials
This page shows Psyence Biomedical Ltd. (PBM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Psyence Biomedical’s reported history shows a capital-funded balance-sheet reset, with fresh financing repeatedly offsetting operating cash burn.
From FY2024 to FY2026, equity flipped from negative to strongly positive and long-term debt disappeared, but that cleaner balance sheet was financed by$23.1M of cash raised across FY2025-FY2026 while operations consumed$11.9M . In other words, the stronger FY2026 balance sheet does not show self-funding; it shows outside capital rebuilding the company faster than operating losses depleted cash.
The brief FY2025 profit of
Total liabilities shrank from
Financial Health Signals
Psyence Biomedical Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Psyence Biomedical Ltd. passes 0 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Psyence Biomedical Ltd. reported a net loss of $6.9M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Psyence Biomedical Ltd. reported -$6.9M in net income in fiscal year 2026. This represents a decrease of 785.6% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Cash & Balance Sheet
Psyence Biomedical Ltd. recorded an outflow of $8.1M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents a decrease of 117.5% from the prior year.
Psyence Biomedical Ltd. held $7.4M in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Margins & Returns
Psyence Biomedical Ltd.'s ROE was -40.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 56.0 percentage points from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Capital Allocation
Psyence Biomedical Ltd. invested $229 in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 97.7% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
PBM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Net Income | -$6.9M-785.6% | $1.0M | N/A | -$3.2M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, EPS (Diluted).
PBM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Total Assets | $17.6M+140.1% | $7.3M+546.2% | $1.1M-28.8% | $1.6M |
| Current Assets | $9.1M+38.9% | $6.6M+482.3% | $1.1M-29.2% | $1.6M |
| Cash & Equivalents | $7.4M+21.3% | $6.1M+736.8% | $733K-45.0% | $1.3M |
| Total Liabilities | $623K+4.8% | $594K-95.1% | $12.1M+576.0% | $1.8M |
| Long-Term Debt | N/A | N/A | $10.4M | N/A |
| Total Equity | $16.9M+152.1% | $6.7M+161.3% | -$11.0M-5374.1% | -$200K |
| Retained Earnings | -$63.4M-12.3% | -$56.4M+1.8% | -$57.5M-812.1% | -$6.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities.
PBM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$8.1M-118.1% | -$3.7M-26.8% | -$2.9M-85.0% | -$1.6M |
| Capital Expenditures | $229-97.7% | $10K+72.5% | $6K | N/A |
| Free Cash Flow | -$8.1M-117.5% | -$3.7M-26.9% | -$3.0M | N/A |
| Investing Cash Flow | -$4.5M-27697.0% | -$16K-183.4% | -$6K | N/A |
| Financing Cash Flow | $14.0M+52.6% | $9.2M+289.5% | $2.4M+100.4% | $1.2M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PBM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Return on Equity | -40.9%-56.0pp | 15.0% | N/A | N/A |
| Return on Assets | -39.5%-53.3pp | 13.8% | N/A | -201.6% |
| Debt-to-Equity | 0.04-0.1x | 0.09 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, FCF Margin.
Similar Companies
Where Psyence Biomedical Ltd. Ranks
Frequently Asked Questions
Is Psyence Biomedical Ltd. profitable?
No, Psyence Biomedical Ltd. (PBM) reported a net income of -$6.9M in fiscal year 2026.
What is Psyence Biomedical Ltd.'s return on equity (ROE)?
Psyence Biomedical Ltd. (PBM) has a return on equity of -40.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Psyence Biomedical Ltd.'s free cash flow?
Psyence Biomedical Ltd. (PBM) recorded an outflow of $8.1M in free cash flow during fiscal year 2026. This represents a -117.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Psyence Biomedical Ltd.'s operating cash flow?
Psyence Biomedical Ltd. (PBM) recorded an outflow of $8.1M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Psyence Biomedical Ltd.'s total assets?
Psyence Biomedical Ltd. (PBM) had $17.6M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Psyence Biomedical Ltd.'s capital expenditures?
Psyence Biomedical Ltd. (PBM) invested $229 in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Psyence Biomedical Ltd.'s debt-to-equity ratio?
Psyence Biomedical Ltd. (PBM) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Psyence Biomedical Ltd.'s return on assets (ROA)?
Psyence Biomedical Ltd. (PBM) had a return on assets of -39.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Psyence Biomedical Ltd.'s cash runway?
Based on fiscal year 2026 data, Psyence Biomedical Ltd. (PBM) had $7.4M in cash against an annual operating cash burn of $8.1M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Psyence Biomedical Ltd.'s Piotroski F-Score?
Psyence Biomedical Ltd. (PBM) has a Piotroski F-Score of 0 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Psyence Biomedical Ltd.'s earnings high quality?
Psyence Biomedical Ltd. (PBM) reported a net loss of $6.9M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.